Journal article icon

Journal article

Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.

Abstract:

Ipilimumab (Yervoy; Medarex and Bristol-Myers Squibb) is a human MAB against cytotoxic T-lymphocyte antigen 4, which enhances co-stimulation of cytotoxic T-lymphocytes, resulting in their proliferation and an anti-tumour response. It is licensed for the treatment of unresectable or metastatic malignant melanoma, while multiple clinical trials using this medication in the treatment of other malignancies are ongoing. As a clinical response to ipilimumab results from immunostimulation, predictab...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1530/eje-12-0167

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, RDM, OCDEM
Role:
Author
Journal:
European journal of endocrinology / European Federation of Endocrine Societies
Volume:
167
Issue:
1
Pages:
1-5
Publication date:
2012-07-05
DOI:
EISSN:
1479-683X
ISSN:
0804-4643
URN:
uuid:eeb139bc-a1e2-4e44-a090-eb4e1413fcf9
Source identifiers:
322716
Local pid:
pubs:322716

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP